Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB) will report first quarter 2026 financial results and provide a corporate update on Thursday, May 14, 2026, at 8:30 a.m. Eastern Time.
The company will host a conference call and webcast, with a replay available on its investor relations website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CLRB
On the day this news was published, CLRB declined 1.29%, reflecting a mild negative market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $172K from the company's valuation, bringing the market cap to $13.14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CLRB is down 6.06% while peers show mixed moves: EDSA down 5.49%, THAR up 5.8%, SYBX up 9.32%. Momentum data flags only LGVN down 8.9%, suggesting CLRB’s move is more stock-specific than sector-driven.
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings date notice | Neutral | +3.6% | Announcement of full-year 2025 results call and webcast scheduling. |
| Nov 06 | Earnings date notice | Neutral | +2.7% | Scheduling third quarter 2025 results release and investor conference call. |
Prior earnings-date announcements for CLRB led to modest positive moves, averaging 3.13% over the last two similar events.
Over recent months, Cellectar reported multiple clinical and financing milestones. On Mar 4, 2026, full-year 2025 results highlighted cash of $13.2M and a net loss of $21.8M, alongside pipeline progress. In April and May 2026, the company advanced CLR 125 into Phase 1b, secured ASCO 2026 data acceptance, and released strong CLOVER WaM outcomes plus an oversubscribed financing of up to $140M. The new earnings-date notice continues this cadence of regular updates.
Historical Comparison
Past earnings-date announcements for CLRB produced average moves of 3.13%, indicating these scheduling updates have historically prompted modest, positive stock reactions.
The company has consistently pre-announced earnings calls, maintaining a pattern of scheduled financial disclosures and accompanying corporate updates.
Market Pulse Summary
This announcement sets the timeline for Q1 2026 financial results and a corporate update on May 14, 2026 at 8:30 a.m. ET. In recent months, Cellectar combined positive Waldenström macroglobulinemia data with significant financing activity and advancing trials such as CLR 125. Investors may focus on cash runway, spending trends, and progress toward pivotal studies when those results are released, given the company’s capital needs and expanding clinical pipeline.
AI-generated analysis. Not financial advice.
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, May 14, 2026 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: Webcast: | 63374 Click HERE |
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
